OCT-1 as a determinant of response to antileukemic treatment
Date
2011
Authors
Engler, J.
Hughes, T.
White, D.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Clinical Pharmacology and Therapeutics, 2011; 89(4):608-611
Statement of Responsibility
JR Engler, TP Hughes and DL White
Conference Name
Abstract
Despite the excellent responses to imatinib therapy observed in patients with chronic phase chronic myeloid leukemia (CP-CML),<sup>1</sup> ∼25% of these patients demonstrate primary resistance or suboptimal response. <sup>2</sup> Inadequate inhibition of the kinase activity of BCR-ABL<sup>3</sup> due to low intracellular concentrations of imatinib achieved in target leukemic cells has been associated with suboptimal response.<sup>4</sup> The organic cation transporter 1 (OCT-1) has been identified as the major active influx pump for imatinib in CML cells,<sup>4,5</sup> and has therefore been investigated as a cause of suboptimal response in patients treated with imatinib. © 2011 ASCPT.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2011 American Society for Clinical Pharmacology and Therapeutics